Flyleaf Wart Remover

Description

No description information is available for the specified drug.

Uses and Indications

This drug is indicated for the removal of warts, including plantar warts, flat warts, common warts, corns, and calluses.

There are no teratogenic or nonteratogenic effects associated with this drug.

Dosage and Administration

The recommended dosage for the medication is 1 ml administered twice daily. This regimen should be maintained for a duration of 15 days.

Healthcare professionals are advised to ensure proper preparation and administration techniques are followed to optimize therapeutic outcomes.

Contraindications

Use of this product is contraindicated in the following situations:

Application is not recommended on irritated skin or any area that is infected, as this may exacerbate the condition. The product should not be used in individuals with known allergies to any of its ingredients, due to the risk of allergic reactions.

Additionally, the product is contraindicated for use on moles, birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes, as these conditions may require different treatment approaches.

Patients with diabetes or poor blood circulation should avoid using this product, as it may pose additional risks. Furthermore, use is contraindicated in pregnant or breastfeeding individuals unless specifically directed by a healthcare practitioner, to ensure safety for both the mother and child.

Warnings and Precautions

For external use only, this product is flammable and must be kept away from fire and flame. It should be stored out of reach of children. Healthcare professionals should advise patients to avoid contact with the eyes; in the event of contact, it is essential to flush the eyes with plenty of cool water. The product should not be ingested; if swallowed, immediate medical attention should be sought or the Poison Control Center (1-800-222-1222) should be contacted.

General precautions must be observed when using this product. It should not be applied to irritated skin or any area that is infected. Patients with known allergies to any ingredient in this formulation should refrain from use. The product is contraindicated for application on moles, birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes. Caution is advised for individuals with diabetes or poor blood circulation. Additionally, pregnant or breastfeeding patients should only use this product if directed by a healthcare practitioner.

Patients should be instructed to discontinue use and contact their healthcare provider if they experience chest pain, rapid heartbeat, faintness, or dizziness. Sudden, unexplained weight gain or swelling of the hands or feet also warrants immediate consultation with a physician.

Side Effects

Patients using this product may experience a range of adverse reactions. Serious adverse reactions that warrant immediate discontinuation of use include chest pain, rapid heartbeat, faintness, dizziness, sudden unexplained weight gain, and swelling of the hands or feet.

In addition to these serious reactions, it is important to note that the product is for external use only and is flammable. Patients should keep the product away from fire and flame, and out of reach of children. Contact with the eyes should be avoided; in the event of contact, patients are advised to flush the eyes with plenty of cool water. If the product is swallowed, medical attention should be sought immediately, or the Poison Control Center should be contacted at 1-800-222-1222.

Drug Interactions

There are currently no documented drug interactions associated with the use of this medication. Additionally, there is no information available regarding interactions with laboratory tests. As such, no specific recommendations for dosage adjustments or monitoring are warranted at this time.

Packaging & NDC

Below are the non-prescription pack sizes of Flyleaf Wart Remover (salicylic acid 20%). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this product out of reach of children and for external use only. Care should be taken to avoid contact with the eyes; in the event of contact, the eyes should be flushed with plenty of cool water. The product should not be swallowed; if ingested, medical attention should be sought immediately or the Poison Control Center (1-800-222-1222) should be contacted.

For application, the affected area should be washed, and warts may be soaked in warm water for 5 minutes as an optional step. A sufficient amount of the product should be applied using a cotton swab to cover each wart, allowing it to dry. This process may be repeated two to three times daily as needed, up to a maximum of 12 weeks, until the wart is removed.

Caution is advised against using the product on irritated skin, infected areas, moles, birthmarks, warts with hair growing from them, genital warts, or warts located on the face or mucous membranes. Additionally, it should not be used in pediatric patients with diabetes or poor blood circulation. The product is contraindicated in individuals who are allergic to any of its ingredients and should not be used during pregnancy or breastfeeding unless directed by a healthcare practitioner.

Skin discoloration may occur during or after use, and the product should be stored at room temperature, avoiding excessive heat above 37°C (99°F).

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

Pregnant patients and those who are breastfeeding should not use this medication unless directed by a healthcare practitioner. The potential risks associated with the use of this medication during pregnancy have not been established, and its safety profile in this population remains unclear. Therefore, healthcare providers are advised to carefully evaluate the benefits and risks before prescribing this medication to women of childbearing potential. It is essential to consider alternative treatments that may be safer during pregnancy and lactation.

Lactation

Lactating mothers should consult a healthcare practitioner before using this medication while breastfeeding. There is no available data on the excretion of this medication in human breast milk or its effects on breastfed infants. Therefore, caution is advised when administering this medication to lactating mothers.

Renal Impairment

There is no specific information available regarding dosage adjustments, special monitoring, or safety considerations for patients with renal impairment. Healthcare professionals should exercise caution when prescribing to patients with reduced kidney function, as the absence of detailed guidance necessitates careful clinical judgment. Regular monitoring of renal function may be advisable in this patient population.

Hepatic Impairment

There is no information available regarding the use of this medication in patients with hepatic impairment. Consequently, there are no dosage adjustments, special monitoring requirements, or precautions specified for individuals with compromised liver function. Healthcare professionals should exercise clinical judgment when considering the use of this medication in patients with liver problems, as the absence of data does not preclude the need for careful evaluation and monitoring in this population.

Overdosage

In the absence of specific overdosage information, it is essential for healthcare professionals to remain vigilant and prepared for potential scenarios involving overdose.

Healthcare providers should be aware that the lack of documented overdosage data does not preclude the possibility of overdose occurring. In such cases, it is recommended to monitor patients closely for any unusual symptoms or adverse reactions that may arise.

Should an overdose be suspected, immediate medical evaluation is advised. Supportive care should be initiated as necessary, and symptomatic treatment should be provided based on the clinical presentation of the patient.

In the event of an overdose, healthcare professionals are encouraged to consult local poison control centers or relevant toxicology resources for guidance on management protocols and potential interventions.

Documentation of the incident and any interventions performed is crucial for ongoing patient care and for informing future clinical decisions.

Nonclinical Toxicology

No teratogenic effects were observed in animal studies. Additionally, there was no increase in fetal malformations noted in these studies. The available data do not indicate any concerns regarding teratogenicity or non-teratogenic effects in the context of the evaluated compounds.

Information regarding animal pharmacology and toxicology was not provided in the insert.

Postmarketing Experience

No specific postmarketing experience details are available in the extracted data. As such, there are no additional adverse events or rare case reports to summarize.

Patient Counseling

Healthcare providers should advise patients to store the medication at room temperature, ensuring it is kept away from excessive heat above 37°C (99°F) to maintain its efficacy.

Additionally, patients should be informed that skin discoloration may occur during or after the use of the medication. It is important for healthcare providers to discuss this potential side effect with patients, allowing them to make informed decisions regarding their treatment and to recognize any changes that may arise during therapy.

Storage and Handling

The product is supplied in various package configurations, with specific NDC numbers available for identification. It should be stored at room temperature, ensuring that the storage environment does not exceed excessive heat above 37°C (99°F). Proper handling is essential to maintain the integrity of the product, and care should be taken to avoid conditions that may compromise its quality.

Additional Clinical Information

Patients should administer the treatment twice daily, using 1 ml each time, with a total supply for 15 days. For optimal results, it is recommended that patients wash the affected area and optionally soak the wart in warm water for 5 minutes prior to application. A sufficient amount of the treatment should be applied using a cotton swab to ensure complete coverage of each wart, allowing it to dry afterward. This process may be repeated two to three times daily as needed until the wart is removed, with a maximum duration of up to 12 weeks.

No additional information is available regarding laboratory tests, abuse potential, or postmarketing experience.